Specific targeting of the GABA-A receptor α5 subtype by a selective inverse agonist restores cognitive deficits in Down syndrome mice. - Wikidata - wikimedia - TriplyDB

Specific targeting of the GABA-A receptor α5 subtype by a selective inverse agonist restores cognitive deficits in Down syndrome mice.

Specific targeting of the GABA-A receptor α5 subtype by a selective inverse agonist restores cognitive deficits in Down syndrome mice.

http://www.wikidata.org/entity/Q35177041

about

Pathophysiological power of improper tonic GABA(A) conductances in mature and immature models.Prospects for Improving Brain Function in Individuals with Down Syndrome Building an adaptive brain across development: targets for neurorehabilitation must begin in infancy Mouse models of Down syndrome as a tool to unravel the causes of mental disabilities Functional regulation of GABAA receptors in nervous system pathologies Neurological phenotypes for Down syndrome across the life span Down Syndrome Cognitive Phenotypes Modeled in Mice Trisomic for All HSA 21 Homologues Monoacylglycerol lipase inhibitor JZL184 improves behavior and neural properties in Ts65Dn mice, a model of down syndrome Selective Pharmacological Augmentation of Hippocampal Activity Produces a Sustained Antidepressant-Like Response without Abuse-Related or Psychotomimetic Effects GABA receptor subunit distribution and FMRP-mGluR5 signaling abnormalities in the cerebellum of subjects with schizophrenia, mood disorders, and autism.GABAA receptor subtypes: Therapeutic potential in Down syndrome, affective disorders, schizophrenia, and autism.Pharmacological approaches to improving cognitive function in Down syndrome: current status and considerations.Hedgehog agonist therapy corrects structural and cognitive deficits in a Down syndrome mouse model Modulation of GABAergic transmission in development and neurodevelopmental disorders: investigating physiology and pathology to gain therapeutic perspectives.Adaptive and pathological inhibition of neuroplasticity associated with circadian rhythms and sleep Differential Alteration in Expression of Striatal GABAAR Subunits in Mouse Models of Huntington's Disease Overexpression of Dyrk1A is implicated in several cognitive, electrophysiological and neuromorphological alterations found in a mouse model of Down syndrome Tonic inhibition in dentate gyrus impairs long-term potentiation and memory in an Alzheimer's [corrected] disease model.The App-Runx1 region is critical for birth defects and electrocardiographic dysfunctions observed in a Down syndrome mouse model.Protein dynamics associated with failed and rescued learning in the Ts65Dn mouse model of Down syndrome.Chronic Treatment with a Promnesiant GABA-A α5-Selective Inverse Agonist Increases Immediate Early Genes Expression during Memory Processing in Mice and Rectifies Their Expression Levels in a Down Syndrome Mouse Model A Sonic hedgehog (Shh) response deficit in trisomic cells may be a common denominator for multiple features of Down syndrome Identification of the translocation breakpoints in the Ts65Dn and Ts1Cje mouse lines: relevance for modeling Down syndrome.Trisomy 21 and early brain development Tc1 mouse model of trisomy-21 dissociates properties of short- and long-term recognition memory.Molecular and cellular alterations in Down syndrome: toward the identification of targets for therapeutics From abnormal hippocampal synaptic plasticity in down syndrome mouse models to cognitive disability in down syndrome.Adult-onset fluoxetine treatment does not improve behavioral impairments and may have adverse effects on the Ts65Dn mouse model of Down syndrome.Deficits in cognition and synaptic plasticity in a mouse model of Down syndrome ameliorated by GABAB receptor antagonists.Pharmacological correction of excitation/inhibition imbalance in Down syndrome mouse models.Short-term treatment with the GABAA receptor antagonist pentylenetetrazole produces a sustained pro-cognitive benefit in a mouse model of Down's syndrome.Weaker control of the electrical properties of cerebellar granule cells by tonically active GABAA receptors in the Ts65Dn mouse model of Down's syndrome.Human chromosome 21 orthologous region on mouse chromosome 17 is a major determinant of Down syndrome-related developmental cognitive deficits Disinhibition, an emerging pharmacology of learning and memory The GABAergic Hypothesis for Cognitive Disabilities in Down Syndrome Benzodiazepine receptor ligands: a patent review (2006-2012).GABAergic dysfunction in pediatric neuro-developmental disorders.Neural oscillations during non-rapid eye movement sleep as biomarkers of circuit dysfunction in schizophrenia.Altered Intrinsic Pyramidal Neuron Properties and Pathway-Specific Synaptic Dysfunction Underlie Aberrant Hippocampal Network Function in a Mouse Model of Tauopathy.Dentate gyrus mediates cognitive function in the Ts65Dn/DnJ mouse model of Down syndrome.

P2860

Q21129461-3D723A4E-15D4-430A-B35F-3C40DB8B5414 Q22252566-21C8FF59-EF49-42AF-AEF9-493CC8610A38 Q26781609-68A6E620-FC50-4C47-8C60-B7B3A5C478A7 Q26863005-724F5A38-3C79-4F5D-9EB2-28AAA52F1233 Q27013597-3820B7D2-084E-452D-A9D4-00FCF2A3E5C0 Q27025698-D679AD44-4497-4518-8C30-880630415255 Q27300997-921EEF5A-9FA5-4DAF-A951-8DD4CD59AAA1 Q28542515-0DE08AC8-DC86-4CFB-937A-890AC1D48B70 Q30354668-CD5640BE-0AC6-4B4D-A46E-69DDE8D9D2B4 Q30363617-FCA980E3-CA08-4780-8EC6-A27F8717A8C0 Q30421260-7C80ECCE-A936-463F-B79D-032ADCC88BCE Q30422188-7E7FD1C1-E7B0-4935-AB21-D02602155B87 Q33552991-CC526402-F2F1-4247-8282-4CEE25C5C421 Q33659830-E53C75D7-82A8-4F36-B89B-419218E13897 Q33764911-2068A3A7-F729-4885-B8F3-C756981C02AE Q33813021-37FCC369-D25B-401F-94D3-FFDDD0443011 Q34133976-02FC7B68-671F-4ABF-9D88-D94A55C4A30E Q34157421-2AB4E875-D7AA-4DFE-B8F7-83D5BB9E5988 Q34302163-1D4EE980-5458-45CD-8A5D-28328C77D4CB Q35202586-872B155E-B0D8-4D91-9191-A34E94A93182 Q35418044-71DECDBE-BE35-406E-844F-CBEBB75B8590 Q35509854-17736AE5-C125-4E9C-9212-22F890E39AB8 Q35573506-D41D1CB8-DBDD-4015-B225-0BE6A5ED5407 Q35740129-60AD588D-F893-43B5-9BC5-A461256AAC6A Q35921438-68A35EA5-D667-4464-A292-FDABBF41B6A9 Q36111546-B2CCF724-013C-4DC0-9529-526BB32C4A48 Q36111747-AEB0C6AB-C4AA-4A36-8332-02AF8097C256 Q36119092-EDE35578-3598-45D1-9221-B77105BFC5F8 Q36138353-065E40AF-D24B-4F4B-BFD5-650904D73CDD Q36177608-86FD3CCB-0B49-4BF0-BC8D-633DA0A601C2 Q36965872-C9253EAC-9394-4877-B790-B0412302C31A Q37045414-192CC54F-2B3E-4ED8-A166-8DC5AA440381 Q37463959-0DA00107-8775-4772-B6C2-228EC924B156 Q37635772-92EC099D-FCB7-4042-B087-2772E6AA0C69 Q37683060-18BAFE75-E553-4ADE-BBD5-D9545957CC10 Q38092169-AABCA3D5-2F30-4CA5-9455-62D3EB0530F7 Q38175971-1B0DC6D4-C7E8-4E19-8E01-20E2DB70786F Q38203026-3716AE53-DBC8-4C53-A9AC-5006E296761D Q38921687-29886142-0317-4017-966E-BDE4CAF693FB Q39294662-09B15B15-71FA-427B-AA26-4846CE1ADEF3

P2860

Specific targeting of the GABA-A receptor α5 subtype by a selective inverse agonist restores cognitive deficits in Down syndrome mice.

http://www.wikidata.org/entity/Q35177041

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Specific targeting of the GABA ...... eficits in Down syndrome mice.

@ast

Specific targeting of the GABA ...... eficits in Down syndrome mice.

@en

type

label

Specific targeting of the GABA ...... eficits in Down syndrome mice.

@ast

Specific targeting of the GABA ...... eficits in Down syndrome mice.

@en

prefLabel

Specific targeting of the GABA ...... eficits in Down syndrome mice.

@ast

Specific targeting of the GABA ...... eficits in Down syndrome mice.

@en

P1433

Q35177041-12D7DD9E-1B07-4E6F-8D55-268351E53356

P1476

Q35177041-0AD6BF70-F6E7-413B-9C69-6CB6F931EA10

P2093

Q35177041-01268CFE-CADC-47A3-97A3-9479BD693F6E

Q35177041-4AD35E91-B003-4CC3-AB95-CE98236CF866

Q35177041-55DEC77B-C6CF-4B5D-9E9E-2E4B7EAEA59A

Q35177041-8BF03488-F72E-4772-A654-5D5809F8262E

Q35177041-A021C65E-6613-44C4-B555-2E52135660DA

Q35177041-A101A984-5E96-42EA-9310-924B7F593326

Q35177041-AECC1D9C-31E9-4066-8E65-164DBE702518

Q35177041-C81808BA-B57D-4A10-B011-EF46766E5324

Q35177041-E0F8D2A3-F36D-4185-8DDB-356B53E7B10D

P2860

Q35177041-02F0D8E5-2369-4532-90AF-6CF2C80A5262

Q35177041-0CD11582-5F64-4F59-90B7-6E2B1549D51D

Q35177041-0F8EF7C6-CE3C-4ADD-924F-7B2FFA3C595D

Q35177041-1BCA1A48-897D-42D0-BE84-20CD107E5087

Q35177041-1C2B35DC-3FCA-469C-8B38-5869EDD0E2CF

Q35177041-32AA6D8C-E080-46C0-8471-3B57DC165D11

Q35177041-50F1EA35-7137-4E3D-853A-CD34064258B4

Q35177041-52204B54-BA07-4859-97EF-63B311D48F85

Q35177041-5AFA4FD3-F29F-4783-9362-8BA27938BA44

Q35177041-60DB4EF7-ACCB-4247-82CA-9FE011B36D78

P304

Q35177041-4372C7A5-72A0-4005-A645-C576BE734901

P31

Q35177041-9281F74B-D3A8-4D77-BE8F-01DAD84BD851

P356

Q35177041-3CEEADDB-83DF-4ECC-B6B1-E45454984107

P407

Q35177041-187E404F-7DE3-4625-B95E-462FADA12FEC

P433

Q35177041-C30C69D2-AC1C-42ED-A838-79B878BB9640

P478

Q35177041-94647F4D-B154-43DF-B946-D058C5505F7B

P50

Q35177041-364BA0AA-FAE6-4BB3-B09E-4D26203EDAFA

P577

Q35177041-F42AB0B9-BF1E-454F-BBEB-E24EBC4392DC

P5875

Q35177041-63D5B3CA-092C-4244-8B7C-62F7B5CCDC19

P698

Q35177041-ADCF131B-5680-4CE8-B0B0-083695003E2D

P932

Q35177041-2778570E-0C0C-4C2C-950E-C87DC6E3F2C9

P356

0269881111405366

P1433

Journal of Psychopharmacology

P1476

Specific targeting of the GABA ...... eficits in Down syndrome mice.

@en

P2093

A Duchon

http://www.w3.org/2001/XMLSchema#string

B Delatour

http://www.w3.org/2001/XMLSchema#string

F de Chaumont

http://www.w3.org/2001/XMLSchema#string

J-C Olivo-Marin

http://www.w3.org/2001/XMLSchema#string

L Dauphinot

http://www.w3.org/2001/XMLSchema#string

M-C Potier

http://www.w3.org/2001/XMLSchema#string

P Lopes Pereira

http://www.w3.org/2001/XMLSchema#string

R H Dodd

http://www.w3.org/2001/XMLSchema#string

Y Hérault

http://www.w3.org/2001/XMLSchema#string

P2860

Behavioral validation of the Ts65Dn mouse model for Down syndrome of a genetic background free of the retinal degeneration mutation Pde6b(rd1).

Autoradiographic localization of alpha5 subunit-containing GABAA receptors in rat brain.

Selective, orally active gamma-aminobutyric acidA alpha5 receptor inverse agonists as cognition enhancers.

An inverse agonist selective for alpha5 subunit-containing GABAA receptors enhances cognition.

An inverse agonist selective for alpha5 subunit-containing GABAA receptors improves encoding and recall but not consolidation in the Morris water maze.

L-655,708 enhances cognition in rats but is not proconvulsant at a dose selective for alpha5-containing GABAA receptors.

GABA(A) receptor subtype-selective efficacy: TPA023, an alpha2/alpha3 selective non-sedating anxiolytic and alpha5IA, an alpha5 selective cognition enhancer.

RO4938581, a novel cognitive enhancer acting at GABAA alpha5 subunit-containing receptors.

Down syndrome--recent progress and future prospects.

Down syndrome, Alzheimer's disease and seizures.

P304

1030-1042

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0269881111405366

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P50

Jérôme Braudeau

P577

2011-06-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51238736

http://www.w3.org/2001/XMLSchema#string

P698

21693554

http://www.w3.org/2001/XMLSchema#string

P932

3160204

http://www.w3.org/2001/XMLSchema#string